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Abstract
Background: The ankyrin repeat and suppressor of cytokine signalling (SOCS) box proteins (Asbs) are a large
protein family implicated in diverse biological processes including regulation of proliferation and differentiation.
The SOCS box of Asb proteins is important in a ubiquitination-mediated proteolysis pathway. Here, we aimed to
evaluate expression and function of human Asb-9 (ASB9).
Results: We found that a variant of ASB9 that lacks the SOCS box (ASB9ΔSOCS) was naturally detected in human
cell lines but not in peripheral blood mononuclear cells or normal hepatocytes. We also identified ubiquitous
mitochondrial creatine kinase (uMtCK) as a new target of ASB9 in human embryonic kidney 293 (HEK293) cells. The
ankyrin repeat domains of ASB9 can associate with the substrate binding site of uMtCK in a SOCS box-
independent manner. The overexpression of ASB9, but not ASB9ΔSOCS, induces ubiquitination of uMtCK. ASB9 and
ASB9ΔSOCS can interact and colocalise with uMtCK in the mitochondria. However, only expression of ASB9
induced abnormal mitochondrial structure and a decrease of mitochondrial membrane potential. Furthermore, the
creatine kinase activities and cell growth were significantly reduced by ASB9 but not by ASB9ΔSOCS.
Conclusions: ASB9 interacts with the creatine kinase system and negatively regulates cell growth. The differential
expression and function of ASB9 and ASB9ΔSOCS may be a key factor in the growth of human cell lines and
primary cells.
Background
The largest family of suppressor of cytokine signalling
(SOCS) box-containing superfamily proteins are the
ankyrin repeat and SOCS box proteins (Asbs; ASBs in
humans). Although 18 members of the Asb family have
been identified in mice and humans, the function of
Asbs has not been clearly defined. The Asbs have two
functional domains, a SOCS box and a variable number
of N-terminal ankyrin (ANK) repeats [1]. The SOCS
box of Asb proteins has two subdomains: a BC box and
a Cul2/Cul5 box. Highly conserved amino acid
sequences of the BC box and the Cul5 box, which are
essential for ensuring that the interaction with elongins
B/C and Cullin 5-Rbx2 forms E3 ubiquitin (Ub) ligase
complexes, are important in a ubiquitination-mediated
proteolysis pathway [2-6]. While SOCS family members
use the SH2 domain to recruit substrates, the ANK
repeat regions of Asb family members serve as specific
protein-protein interaction platforms to recruit target
substrates in different biological processes [1]. Asb-2
targets the actin-binding proteins filaments A and B for
proteasomal degradation. Heuze et al.h a v es h o w nt h a t
Asb-2 may regulate haematopoietic cell differentiation
by modulating the cell-spreading process [4]. ANK
repeats of Asb-3 interact with the C-terminus of tumour
necrosis factor (TNF)-R2 and act as a negative regulator
of the TNF-R2-mediated cellular response [3]. The ANK
repeat of Asb-4 interacts with the factor-inhibiting
HIF1a (FIH); it is also a hydroxylation substrate of FIH
and promotes vascular differentiation [7]. Asb-15 report-
edly regulates protein synthesis in skeletal muscle and
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phosphorylation of mitogen-activated protein kinase and
Akt [8,9].
Creatine kinases (CKs) are a large family of isoen-
zymes involved in high-energy phosphate metabolism.
Five isoforms of CK have been identified in mammals:
three in cytosol, namely CKB (brain type), CKM (mus-
cle type) and CKMB (mixed type); and two in mito-
chondria, namely ubiquitous mitochondrial CK
(uMtCK) and sarcomeric MtCK (sMtCK) [10,11]. CKs
regulate levels of ATP in subcellular compartments,
where they provide ATP molecules at sites of fluctuat-
ing energy demand of very specialised cells, such as
muscle fibres, neurons, or sperm cells, by the transfer of
phosphates between creatine and adenine nucleotides
and immediate regeneration of ATP. The CKs are also
necessary for maintaining the normal function of many
other cells, including kidney, placenta, pancreas, thymus,
thyroid, and intestinal epithelial cells, as well as
endothelial cells, cartilage and bone cells, macrophages,
and blood platelets, possibly by a continuous delivery of
high-energy phosphates to the site of ATP utilisation
[10-14].
Abnormal expression and activity of CKs have been
shown in tumours and diseases [11,15,16]. The cytosolic
CKB is induced in a variety of tumours, including neu-
roblastoma, small cell lung carcinoma, colon adenocarci-
noma, and breast carcinoma. Because the tumour
suppressor p53 is involved in the repression of CKB
transcription, CKB may be increased in tumours with
mutations in p53 alleles [17]. MtCK is known as a pri-
mary target of oxidative and radical-induced molecular
damage; and the impairment of MtCK has been
reported in ischaemia, cardiomyopathy, and neurode-
generative disorders [18,19]. Upregulation of MtCK has
also been shown in creatine-depleted muscles and in
patients with mitochondrial cytopathies, which may
explain the mechanism of compensating for the func-
tional impairment of the energy state control. Overex-
pression of MtCK in tumours has also been reported
[20-22]. Hence, CKs and creatine analogues are consid-
ered a new target of chemotherapeutics for cancer.
A recent report shows that ASB9 interacts with crea-
tine kinase B CKB in human embryonic kidney 293
(HEK293) cells, indicating that human Asb-9 (ASB9)
mediates the ubiquitination and proteasomal degrada-
tion of CKB in cells [23]. ASB9 was isolated as a
potential biomarker for breast cancer [24]. In this
study, we report that a variant of ASB9 that lacks a
SOCS box was naturally detected in human cell lines
but not in human primary cells. We also demonstrate
that ASB9 interacts with uMtCK and induces malfunc-
tion of mitochondria, leading to negative regulation of
cell growth.
Results
Identification of a variant form of ASB9 in human cell
lines
We used reverse transcription polymerase chain reaction
(RT-PCR) to analyse the expression pattern of 18 mem-
bers of the ASB family in human cell lines and human
peripheral blood mononuclear cells (hPBMCs). As shown
in Figure 1, two bands of ASB9 PCR products (115 bp of
expected size and 175 bp of longer size) were detected in
human cell lines. However, hPBMC expressed only one
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Figure 1 Expression of 18 members of the ankyrin repeat and
suppressor of cytokine signalling (SOCS) box protein (Asb)
family in human cell lines and human peripheral blood
mononuclear cells (hPBMCs). The human keratinocyte (HaCaT),
human embryonic kidney 293 (HEK293), RPMI 8226, THP-1, KG-1,
and human peripheral blood mononuclear cells were cultured for 1
day before total RNA isolation. The total RNAs were extracted and
reverse transcribed to generate cDNAs. A total of 1 μl of the cDNA
mixture was subjected to the standard PCR reaction for 25 cycles
with the primer sets as described in Table 2. The b-actin expression
level was used as a control. The letter M denotes a standard DNA
marker.
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Page 2 of 22band of ASB9. Nucleotide sequence analysis of the
two cDNA bands shows that the shorter band repre-
sents the ASB9 gene (GenBank accession number,
NM_001031739). Interestingly, the longer PCR product
represented a splicing variant of ASB9 (GenBank acces-
sion number, NM_024087). We amplified cDNA
sequences that encoded full-length open reading frames
of ASB9 and the variant from HEK293 cells by RT-PCR.
When we deduced the amino acid sequences from the
cDNAs, we found the splicing variant encodes a smaller
protein with a deletion of the SOCS box domain from
ASB9, which we named ASB9ΔSOCS (Figure 2). ASB9
and ASB9ΔSOCS have six ankyrin repeats.
To examine the tissue distribution of the ASB9
expression, we performed real-time PCR analysis on
cDNAs prepared from human adult tissues. The ASB9
mRNA was expressed predominantly in the testes, kid-
ney, and liver (Figure 3a). The ASB9 and ASB9ΔSOCS
expression was detected in human cell lines such as the
leukaemia and hepatoma cell lines at the mRNA and
protein levels (Figure 3b, c). Interestingly, the ASB9Δ-
SOCS expression was undetectable in the hPBMCs from
diverse blood samples and human normal hepatocytes
(Figure 3b, c). However, a mouse Asb-9 without SOCS
box (mAsb-9ΔSOCS) was not detected in the mouse
cell lines and tissues (Figures 2 and 3d).
Association of ASB9 with CKs and ubiquitin ligase
complexes
Because SOCS box-containing proteins associate with
substrate proteins for degradation, immunocomplexing
assays were performed to identify the ASB9 interacting
proteins (Figure 4a). An anti-Myc antibody was used to
generate immunocomplexes from HEK293 cells that sta-
bly express null, Myc-tagged ASB9 or ASB9ΔSOCS pro-
teins. The proteomic analysis suggests that the main
protein associated with ASB9 and ASB9ΔSOCS is CKB.
Peptide fragments detected by mass spectroscopy show
27% sequence coverage of the total amino acids of CKB
(Figure 4b and Table 1); this result confirms that ASB9
interacts with endogenous CKB in a SOCS box-indepen-
dent manner. Note also that ASB9, but not ASB9Δ-
SOCS, coimmunoprecipitated with Cullin 5, elongin B
and elongin C (Figure 4a and Table 1). This behaviour
indicates that ASB9 interacts with endogenous Cullin 5
and elongin B/C through its SOCS box, which is consis-
tent with a recent report [23]. Additionally, we isolated
another peptide sequence from uMtCK, even though
ASB9        MDGKQGGMDGSKPAGPRDFPGIRLLSNPLMGDAVSDWSPMHEAAIHGHQLSLRNLISQGW    60 
ASB9 SOCS   MDGKQGGMDGSKPAGPRDFPGIRLLSNPLMGDAVSDWSPMHEAAIHGHQLSLRNLISQGW    60
mAsb-9      MDGEQRGRS-DRPGGSPHLP---FLSNPLMGDVVSDWSPLHDAAIHGCLLTLRNLISQGW    56 
*** * *     * *    *    ******** ******   ******** ********* 
ASB9        AVNIITADHVSPLHEACLGGHLSCVKILLKHGAQVNGVTADWHTPLFNACVSGSWDCVNL    120 
ASB9 SOCS   AVNIITADHVSPLHEACLGGHLSCVKILLKHGAQVNGVTADWHTPLFNACVSGSWDCVNL    120
mAsb-9      PVNIITADHVSPLHEACLRGHLSCASVLLSHGAQVNGMTIDWRTPLFNACVSGSQDCVNL    116
***************** *****   ** ******* * ** *********** *****
ASB9        LLQHGASVQPESDLASPIHEAARRGHVECVNSLIAYGGNIDHKISHLGTPLYLACENQQR    180 
ASB9 SOCS   LLQHGASVQPESDLASPIHEAARRGHVECVNSLIAYGGNIDHKISHLGTPLYLACENQQR    180
mAsb9       LLQHGATPHPETELASPIHEAAKRGYVKCIESLAAHGANIDYNISHLGTPLYVACKNQQV    176 
******   **  ********* ** * *  ** * * ***  ********* ** *** 
ASB9        ACVKKLLESGADVNQGKGQDSPLHAVARTASEELACLLMDFGADTQAKNAEGKRPVELVP    240 
ASB9 SOCS   ACVKKLLESGADVNQGKGQDSPLHAVARTASEELACLLMDFGADTQAKNAEGKRPVELVP    240
mAsb-9      ACAKKLLESGVSVNQGKGLDSPLHVVARMSSVELVHLLMDFGANAQAKNADGKRPVDLVP    236 
** *******  ****** ***** ***  * **  *******  ***** ***** ***
ASB9        PESPLAQLFLEREGPPSLMQLCRLRIRKCFGIQQHHKITKLVLPEDLKQFLLHL          294 
ASB9 SOCS   PESPLAQLFLEREG----------------------------------------ASLPKPKP  262
mAsb-9      LESPLIQIFLQNEGPQSLRQLCRLRIRKCFGIRQHHKISELLLPEDLKRFLLHL    290 
**** ****  *** ** ************* ****   * ****** *****
Figure 2 Sequences of human ankyrin repeat and suppressor of cytokine signalling (SOCS) box protein 9 (ASB9), ASB9ΔSOCS and
mAsb-9. CLUSTAL alignment [39] of ASB9, ASB9ΔSOCS, and mAsb-9; the location of the N-terminal ankyrin (ANK) repeats and the SOCS box
motif are shown.
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Page 3 of 22Figure 3 Expression patterns of human ankyrin repeat and suppressor of cytokine signalling (SOCS) box protein 9 (ASB9) and
ASB9ΔSOCS. (a) The expression level of ASB9 mRNA was analysed by real-time PCR using the cDNAs from indicated human tissues. The mRNA
levels were normalised using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control, and relative expression was
determined by dividing all normalised values within a data set by the normalised arbitrary units of the control. (b) Expression of ASB9 in human
cell lines and human peripheral blood mononuclear cells (hPBMCs). (c) Expression of ASB9 in human hepatoma cell lines and normal human
hepatocytes. The expression of ASB9 mRNA and protein was analysed by means of reverse transcription (RT)-PCR and immunoblotting,
respectively. The b-actin expression level was used as a control. (d) Expression of mAsb-9 in mouse cell lines and lymphoid tissues. The GAPDH
expression level was used as an mRNA control. The expression of mAsb-9 protein in the mouse cell lines and primary cells was analysed by
immunoblotting with anti-ASB9 antibody. The b-actin expression level was used as a protein control.
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T10  359 - 366    1031.5500  1030.5427 (K)LLIEMEQR(L)
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Figure 4 Identification of human ankyrin repeat and suppressor of cytokine signalling (SOCS) box protein 9 (ASB9) binding proteins.
(a) Cell lysates were prepared from human embryonic kidney 293 (HEK293) cells that were stably transfected with the indicated expression
vectors; immunoprecipitates were then generated by using an antibody to Myc epitope, after which they were resolved by SDS-PAGE and
stained with Coomassie brilliant blue G-250. (b) The protein bands coimmunoprecipitated with ASB9 were digested in gel with trypsin, and the
samples were analysed by electrospray ionization-time of flight mass spectrometry/mass spectrometry (ESI-TOF MS/MS). MS/MS analyses of the
mass peaks (arrow) obtained from the 45-kDa band reveal the peptide spectra of CKB and ubiquitous mitochondrial creatine kinase (uMtCK).
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Page 5 of 22the sequence contained only 15 amino acids and cov-
ered only 4% of the entire uMtCK sequence (Figure 4b
and Table 1). Importantly, the sequence corresponds to
the C-terminal region (amino acids 367 to 381) of
uMtCK where the sequence shows only 27% identity
with CKB (Figure 4b).
Given that the isoforms of CK are highly homologous,
we decided to check the CK-binding specificity of ASB9 in
the HEK293 cells. First, the expression of endogenous
CKB and uMtCK was identified by immunoblotting analy-
sis. In contrast, the expression of CKM and sMtCK was
not observed (Figure 5a). Next, the interaction specificity
between ASB9 and CKs was determined by immunocom-
plexing assays. In HEK293 cells that stably express Myc-
tagged ASB9 and ASB9ΔSOCS, endogenous CKB and
uMtCK coimmunoprecipitated with ASB9 and ASB9Δ-
SOCS (Figure 5b). In agreement with mass spectroscopy
analysis (Figure 4), ASB9, but not ASB9ΔSOCS, coimmu-
noprecipitated with elongin B. To further confirm endo-
genous interaction of these proteins, immunocomplexes
were obtained using anti-ASB9 antibody and cell lysates
from two cell lines HEK293 and Huh-7 and analysed by
immunoblotting (Figure 6). As expected, all of the proteins
CKB, uMtCK and elongin B were identified in the immu-
noprotein complexes. Others have previously shown inter-
action of ASB9 with CKB [23], but the interaction with
uMtCK is a new finding. We therefore decided to check
the interaction of ASB9 with uMtCK in detail.
Interaction of the ANK repeats of ASB9 with the
substrate binding site of uMtCK
To clarify the interaction between ASB9 and uMtCK, we
used a coimmunocomplexing assay and mapped the
r e g i o n so fA S B 9a n du M t C Ki n v o l v e di nt h ep r o t e i n -
protein interaction. To determine which region of ASB9
is essential for binding to uMtCK, a series of Myc-
tagged ASB9 deletion constructs that encode various
numbers of ANK repeat motifs was made (Figure 7a)
and cotransfected with haemagglutinin (HA)-tagged
uMtCK constructs into HEK293 cells. The coimmuno-
complexing assay shows that ASB9 interacted with
uMtCK in a SOCS box-independent manner (Figure 7b,
lower right). However, the deletion of ANK repeat 1
(ASB9ΔANK1) abrogated its interaction with uMtCK
(Figure 7b, lower right). Further deletion of the remain-
ing ANK repeats showed the same consequences as the
deletion of the first ANK repeat (ASB9ΔANK1), sug-
gesting that ANK repeat 1 is essential for ASB9 and
uMtCK interactions.
CKs are divided into three subdomains: a substrate
binding site, an N-terminal catalytic domain, and a C-
terminal catalytic domain. The substrate binding site is
expected to recruit interacting proteins [25,26]. To
determine whether the substrate binding site of uMtCK
is essential for its interaction with ASB9, we constructed
a HA-tagged substrate binding site (BS) deletion mutant
(uMtCKΔBS) (Figure 8a) and cotransfected it with Myc-
t a g g e dA S B 9c o n s t r u c t si n t oH E K 2 9 3c e l l s( F i g u r e8 b ) .
Both ASB9 and ASB9ΔSOCS coimmunoprecipitated
with uMtCK but not with uMtCKΔBS (Figure 8b, lower
right). These results indicate that the ANK repeat
domains of ASB9 can associate with the substrate bind-
ing site of uMtCK in a SOCS box-independent manner.
The ASB9-induced ubiquitination and degradation of
uMtCK
Because ASB9 assembles with an ubiquitin ligase com-
plex (Figure 4), ubiquitination of ASB9-associated pro-
teins (CKB and uMtCK) was evaluated by in vivo
ubiquitination assays. When uMtCK and ubiquitin were
introduced, high-molecular-weight bands representing
the ubiquitination of the associated proteins were clearly
detected in the ASB9-expressing HEK293 cells (Figure
9a). The polyubiquitinated proteins accumulated in the
presence of MG-132 (Figure 9b). In contrast, significant
ubiquitination of the ASB9-interacting proteins was not
observed in the cells that express ASB9ΔSOCS, probably
because ASB9ΔSOCS can’t assemble with an Ub ligase
complex (Figure 9).
To confirm ASB9-dependent CK ubiquitination, we
performed an in vitro ubiquitination assay (Figure 10).
The lysates of null, Myc-tagged ASB9 or ASB9ΔSOCS
expressing cells were immunoprecipitated with anti-
CKB (Figure 10a) or anti-uMtCK antibodies (Figure
10b), and the ubiquitination of CKB and uMtCK was
monitored. Polyubiquitination was not observed in the
Table 1 Proteins identified by mass spectrometry
Identified proteins GenBank accession no. Molecular weight (kDa) Matched peptides Sequence coverage
CKB AAC31758 43 106 27%
uMtCK NP066270 46 15 4%
Cullin 5 NP003469 91 86 11%
Elongin B AAC08452 18 32 44%
Elongin C NP005639 10 20 17%
The protein bands coimmunoprecipitated with human ankyrin repeat and suppressor of cytokine signalling (SOCS) box protein (ASB9) (Figure 4a) were digested
in gel with trypsin, and the samples were analysed by electrospray ionization-time of flight mass spectrometry/mass spectrometry (ESI-TOF MS/MS).
CKB = creatine kinase B; uMtCK = ubiquitous mitochondrial CK.
Kwon et al. BMC Biology 2010, 8:23
http://www.biomedcentral.com/1741-7007/8/23
Page 6 of 22B
100
75
50
37
25
20
150
100
75
50
37
25
20
150
Lysates
Empty vector
ASB9
ASB9
SOCS
Empty vector
ASB9
ASB9
SOCS
Empty. vector
ASB9
ASB9
SOCS
anti-CKB anti-uMtCK IB  :     anti-Myc
37
25
20
15
50
anti- -actin
Empty vector
ASB9
ASB9
SOCS
Empty vector
ASB9
ASB9
SOCS
anti-Elongin B
-
- -
-
-
-
-
-
- -
-
-
-
-
-
100
75
50
37
25
20
150
- -
-
-
-
-
-
-
- -
-
100
75
50
37
25
20
150-
- -
-
-
-
-
Empty vector
ASB9
ASB9
SOCS
Empty vector
ASB9
ASB9
SOCS
Empty vector
ASB9
ASB9
SOCS
Empty vector
ASB9
ASB9
SOCS
37
25
20
15
50
IP : anti-Myc
anti-CKB anti-uMtCK anti-Elongin B IB   :        anti-Myc
-
- -
-
-
-
-
-
-
- -
-
100
75
50
37
25
20
150 -
- -
-
-
-
-
100
75
50
37
25
20
150 -
- -
-
-
-
-
100
75
50
37
25
20
150
MW
kDa
MW
kDa
MW
kDa
MW
kDa
MW
kDa
MW
kDa
MW
kDa
MW
kDa
MW
kDa
ASB9
SOCS
ASB9
HepG2
Huh-7
SNU-398
SNU-423
SNU-739
SNU-761
Normal 
hepatocytes
uMtCK
-actin
CKB
IB
A
uMtCK
CKB
-actin
IB
CKM
sMtCK
CKM
sMtCK
HaCaT
HEK293
RPMI 8226
KG-1
hPBMCs
THP-1
Figure 5 Creatine kinase (CK)-binding specificities of human ankyrin repeat and suppressor of cytokine signalling (SOCS) box protein
9 (ASB9). (a) Expression of CKs in human normal hepatocytes human hepatoma cell lines and normal human hepatocytes. Whole lysates were
subjected to immunoblotting (IB) with anti-CKB, anti-ubiquitous mitochondrial CK (uMtCK), and anti-CKM, and anti-sarcomeric MtCK (sMtCK)
antibodies. The b-actin expression level was used as a control. (b) Association of ASB9 with CKB and uMtCK. The human embryonic kidney 293
calls (HEK293) cells were stably transfected with empty, Myc-tagged ASB9 and ASB9ΔSOCS expression vectors. Whole lysates or
immunoprecipitates obtained with the anti-Myc antibody were subjected to immunoblotting (IB) analysis with anti-Myc, anti-CKB, anti-uMtCK,
and anti-elongin B antibodies.
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Page 7 of 22absence of ubiquitin. With ubiquitin, the polyubiquitina-
tion of CKB or uMtCK proteins was clearly detected in
the presence of ASB9, and only weak polyubiquitination
was seen in ASB9ΔSOCS or the empty vector control,
probably because of the endogenous ASB9 activity (Fig-
ure 10). There were protein bands that migrate at a
molecular weight less than CKB or uMtCK alone prob-
ably because of partial protein degradation. Thus, the
r e s u l t ss t r o n g l yi n d i c a t et h a tA S B 9i si n v o l v e di nt h e
recruitment, ubiquitination, and degradation of CKB
and uMtCK through the SOCS box.
To investigate the long-term effect of ASB9 expression
in vivo, we analysed the expression of CKB and uMtCK
after culture of stable cell lines for 10 passages.
Immunoblotting analysis with cell lysates and anti-Myc
immunoprecipitates reveal that the protein levels of
endogenous CKB and uMtCK were dramatically reduced
in the HEK293 cells that stably express ASB9 but not in
ASB9ΔSOCS (Figure 11). These results suggest that the
ubiquitination and degradation by ASB9 do affect the
protein levels of target proteins in the cells.
Colocalisation of ASB9 and uMtCK in the mitochondria
and influence of ASB9 expression on the mitochondrial
membrane potential
Given that endogenous uMtCK can interact with ASB9
(Figure 4), we evaluated whether ASB9 colocalises with
endogenous uMtCK in the mitochondria. The cellular
100
75
50
37
25
20
150
100
75
50
37
25
20
150
Lysates
HEK293
Huh-7
HEK293
Huh-7
HEK293
Huh-7
anti-CKB anti-uMtCK IB :  anti-ASB9
37
25
20
15
50
anti- -actin
HEK293
Huh-7
HEK293
Huh-7
anti-Elongin B
-
- -
-
-
-
-
-
- -
-
-
-
-
-
100
75
50
37
25
20
150
- -
-
-
-
-
-
-
- -
-
100
75
50
37
25
20
150-
- -
-
-
-
-
37
25
20
15
50
IP : anti-ASB9
anti-CKB anti-uMtCK anti-Elongin B IB :   anti-ASB9
-
- -
-
-
-
-
-
-
- -
-
100
75
50
37
25
20
150 -
- -
-
-
-
-
100
75
50
37
25
20
150 -
- -
-
-
-
-
100
75
50
37
25
20
150
MW
kDa
MW
kDa
MW
kDa
MW
kDa
MW
kDa
MW
kDa
MW
kDa
MW
kDa
MW
kDa
HEK293
Huh-7
HEK293
Huh-7
HEK293
Huh-7
HEK293
Huh-7
ASB9
ASB9
SOCS
ASB9
B
A
Figure 6 Expression and creatine kinase (CK)-binding specificities of endogenous human ankyrin repeat and suppressor of cytokine
signalling (SOCS) box protein 9 (ASB9). (a) Expression of endogenous ASB9 and ASB9ΔSOCS. Cell lysates of human embryonic kidney 293
(HEK293) cells and Huh-7 cells were used to show endogenous expression of ASB9 and ASB9ΔSOCS. Endogenous expression of CKB,
mitochondrial CK (MtCK), elongin B was also confirmed by immunoblotting. (b) CK-binding activity of endogenous ASB9. The
immunoprecipitates obtained with the anti-ASB9 antibody were analysed by immunoblotting (IB) with anti-ASB9, anti-CKB, anti-uMtCK, and anti-
elongin B antibodies.
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Figure 7 Interaction of human ankyrin repeat and suppressor of cytokine signalling (SOCS) box protein (ASB9) with ubiquitous
mitochondrial creatine kinase (uMtCK). (a) Schematic diagram of the ASB9 and a series of ASB9 N-terminal ankyrin (ANK) deletion mutants.
(b) ANK repeats of ASB9 are required for uMtCK interaction. Myc-tagged ASB9 and a series of ANK deletion mutants were transiently
cotransfected with haemagglutinin (HA)-tagged uMtCK into human embryonic kidney 293 (HEK293) cells. Cell lysates and an immunocomplex of
the anti-Myc antibody were analysed by immunoblotting with anti-Myc or anti-HA antibodies.
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Figure 9 Suppressor of cytokine signalling (SOCS) box-dependent ubiquitination of creatine kinase B (CKB) and ubiquitous
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Page 11 of 22localisation of protein was analysed by immunofluores-
cence staining and confocal imaging. The expression of
DSRed2-Mito was used as a mitochondrial marker. Colo-
calisation of DSRed2-Mito and uMtCK in mitochondria
was observed as expected (Figure 12a). Furthermore,
ASB9 was detected in the cytosol, which also includes
mitochondria, though no ASB9 was detected in the
nucleus. Moreover, uMtCK and either ASB9 or ASB9Δ-
SOCS colocalised in the mitochondria; this colocalisation
is in agreement with the result of in vitro association of
uMtCK with ASB9 that occurs in a SOCS box-indepen-
dent manner (Figures 4, 5, 6, 7, 8). Interestingly, an
abnormal mitochondrial structure was observed in the
ASB9-expressing HEK293 cells (Figure 12a, middle
panel). To investigate mitochondrial structure in the cells
in detail, we compared the architecture of mitochondria
with the aid of DSRed2-Mito and three-dimensional ana-
lysis of confocal data and found rounding and swelling of
mitochondria in ASB9 expressing cells (Figure 12b and
Additional files 1 and 2). These results revealed that the
ASB9 interacts and colocalises with uMtCK in the mito-
chondria, leading to structural organisation defects,
which occur in a SOCS box-dependent manner.
To directly investigate the correlation of ASB9-induced
change in the mitochondrial structure with mitochondrial
function, we used tetramethylrhodamine ethyl ester
(TMRE) to analyse the mitochondrial membrane potential
(ΔΨm). TMRE is a highly fluorescent cationic lipophilic
dye used to determine the value of ΔΨm based on the
fluorescence intensity [27]. The membrane potential ΔΨm
was detected in the control HEK293 cells and shifted left-
ward in the presence of the uncoupler, carbonyl cyanide
p-(trifluoromethoxy) phenylhydrazone (FCCP), indicating
the depolarisation of ΔΨm (Figure 13a, left panel). The
ΔΨm in the cells that stably express ASB9 was significantly
lower than that of the control cells, which is similar to the
membrane potential in the presence of the uncoupler,
indicating the dissipation of ΔΨm in the ASB9 expressing
cells (Figure 13a, middle panel). In the ASB9ΔSOCS
expressing cells, the membrane potential was similar to
that of the control cells (Figure 13a, right panel). This
result suggests that the ubiquitination and degradation of
uMtCK in ASB9-expressing cells is associated with a
change in the mitochondrial structure and ΔΨm, which
results in a significantly impaired mitochondrial function
that may change a variety of cellular functions. To further
confirm the correlation of ASB9 expression and ΔΨm, we
analysed ΔΨm in the PBMC, RPMI 8226 cells and KG-1
cells (Figure 13b). The ΔΨm in the PBMC (expressing
ASB9 but not ASB9ΔSOCS) was significantly lower than
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Figure 10 In vitro ubiquitination of creatine kinase B (CKB) and ubiquitous mitochondrial CK (uMtCK) by human ankyrin repeat and
suppressor of cytokine signalling (SOCS) box protein 9 (ASB9). Whole cell lysates were prepared from human embryonic kidney 293
(HEK293) cells that stably express null (empty vector), Myc-tagged ASB9 or ASB9ΔSOCS and then immunoprecipitated with anti-CKB antibody (a)
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An immunoglobulin heavy chain is shown as an antibody amount control.
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Page 12 of 22that of the RPMI 8226 cells and KG-1 cells. The dissipa-
tion of ΔΨm in the presence of the uncoupler was hardly
detected in the PBMC. These results potentially support
that the regulation of ASB9 and ASB9ΔSOCS expression
may be a critical factor for the different capability of
growth in primary cells and cell lines.
Effect of ASB9 on CK activity
The CKB in the cytosol and the uMtCK in the mito-
chondria interact with ASB9 and are degraded by ASB9
(Figures 4, 5, 6, 7, 8, 9, 10, 11). Thus, the correlation of
CK activity with the ASB9 expression was investigated
in the HEK293 cells that stably express ASB9 or
ASB9ΔSOCS (Figure 14). The total cellular CK activity
was reduced only in the HEK293 cells that express
ASB9 but not ASB9ΔSOCS. Next, the CK activity was
compared in the cytosol and mitochondrial fractions.
The cytosolic and mitochondrial types of CK activity
were both reduced in the ASB9-expressing cells (Figure
14a). However, there was no significant reduction in the
CK activity in the cells that express ASB9ΔSOCS. To
confirm the correlation of CK activity with the ASB9
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Figure 11 Degradation of creatine kinase B (CKB) and ubiquitous mitochondrial CK (uMtCK) by human ankyrin repeat and suppressor
of cytokine signalling (SOCS) box protein 9 (ASB9) after long-term culture. (a) After culture of 10 passages of human embryonic kidney
293 (HEK293) cells stably transfected with Myc-tagged ASB9 and ASB9ΔSOCS expression vectors, cell lysates were immunoblotted with anti-Myc,
anti-CKB, anti-uMtCK, and anti-elongin B antibodies. b-actin was used as a protein amount control. (b) The lysates obtained from HEK293 cells
stably transfected with Myc-tagged ASB9 and ASB9ΔSOCS expression vectors were immunoprecipitated with an anti-Myc antibody and subjected
to immunoblotting with anti-Myc, anti-CKB, anti-uMtCK, and anti-elongin B antibodies.
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Page 13 of 22expression, we analysed CK activity from human cell
lines, PBMCs and normal hepatocytes. The total cellular,
cytosolic and mitochondrial types of CK activity were
significantly reduced in the PBMCs and normal hepato-
cytes that express ASB9 but not ASB9ΔSOCS (Figure
14b). Furthermore, the mitochondrial type of CK activity
in the THP-1 and Huh-7 cells (expression of low level
uMtCK, Figure 3c) was lower than that of the other
human cell lines (Figure 14b). To confirm the activity of
CKB and uMtCK more accurately, these proteins were
immunoprecipitated with anti-CKB and anti-uMtCK,
and the activity of the immunocomplexes was measured.
As shown in Figure 14c, ASB9 clearly abolished the CK
activity of CKB and uMtCK. The CK activity of uMtCK
was also decreased in the presence of ASB9ΔSOCS.
These results imply that the association of ASB9ΔSOCS
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Figure 12 Colocalisation of human ankyrin repeat and suppressor of cytokine signalling (SOCS) box protein 9 (ASB9) and ubiquitous
mitochondrial creatine kinase (uMtCK) in mitochondria. The pDSRed2-Mito vector was transfected into human embryonic kidney 293 (HEK293)
cells that stably express null (empty vector), Myc-tagged ASB9 or ASB9ΔSOCS. After 24 h incubation, the cells were fixed with 4% paraformaldehyde.
(a) A confocal laser scanning microscopy was used to visualise the location of individual proteins with the aid of the mouse anti-Myc antibody (for
ASB9, purple) and the goat anti-uMtCK antibody (green), respectively. DSRed2-Mito was expressed in mitochondria as a red colour. Cells were stained
with Hoechst no. 33258 to visualise the nuclei (blue colour). (b) A confocal laser scanning microscope was used to visualise the structure of
mitochondria with the aid of DSRed2-Mito. Three-dimensional movies of the figures are available as Additional files 1 and 2.
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Page 14 of 22with uMtCK may reduce the enzymatic activity even
though uMtCK is not ubiquitinated and degraded. They
also confirm that the involvement of ASB9 in the crea-
tine kinase system depends on the SOCS box.
Effect of ASB9 on cell growth
To investigate the correlation of ASB9 with cell growth,
we performed a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay on the HEK293
cells that stably express ASB9 or ASB9ΔSOCS. The cell
growth was markedly delayed in the cells that express
ASB9 but not ASB9ΔSOCS (Figure 15a). Given that the
MTT assay measures the mitochondrial dehydrogenase
enzyme activity [28], we deduce from the results that
ASB9 is directly involved in the mitochondrial function
and cell growth. Additionally, we obtained the same
r e s u l t sw h e nw ec h e c k e dt h ec e l lg r o w t hb yu s i n gt h e
trypan blue exclusion method (Figure 15b).
Discussion
Because Asbs interact with a wide variety of target sub-
strates via ankyrin repeat domains, they have diverse
functions such as regulation of proliferation, differentia-
tion, carcinogenesis, and regulation of the cell cycle.
Therefore, ASBs may be differentially expressed between
cell lines and primary cells. Here, we evaluated expres-
sion and function of ASB9 in detail. When investigating
the expression of ASBs, we detected a splicing variant of
the ASB9 that lacks a SOCS box (ASB9ΔSOCS) in sev-
eral cell lines. Recently, ASB9 was reported to interact
with CKB in HEK293 cells, indicating that ASB9 med-
iates ubiquitination and proteasomal degradation of
CKB in the cells. The investigators artificially deleted
the SOCS box by using recombinant biotechnology and
proved that the SOCS box of ASB9 mediates interac-
tions with the elongin B/elongin C/Cullin 5 complex by
functioning as an adaptor for an E3 ubiquitin ligase
Figure 13 Effect of human ankyrin repeat and suppressor of cytokine signalling (SOCS) box protein 9 (ASB9) on the mitochondrial
membrane potential (ΔΨm). (a) Human embryonic kidney 293 (HEK293) cells that stably express null (empty vector), Myc-tagged ASB9, or
ASB9ΔSOCS were trypsinised for 5 min and incubated in 50 nM tetramethylrhodamine ethyl ester (TMRE) with (full line) or without (dotted line)
200 nM carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP) for 30 min at 37°C in the dark. The TMRE fluorescence in the cells was
analysed by flow cytometry. The low fluorescence indicates a loss of ΔΨm. (b) The ΔΨm of peripheral blood mononuclear cells (PBMCs), RPMI
8226 cells, and KG-1 cells were analysed as described in (a).
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Page 15 of 22Figure 14 Effect of human ankyrin repeat and suppressor of cytokine signalling (SOCS) box protein 9 (ASB9) on creatine kinase (CK)
activity. (a) The cellular CK activity was measured during a 4-day culture of the human embryonic kidney 293 (HEK293) cells that stably express
null, Myc-tagged ASB9, or ASB9ΔSOCS. The cell lysates (total cells), cytosolic fraction and mitochondrial fraction were prepared, and the CK
activity was determined. (b) The cell lysates (total cells), cytosolic fraction and mitochondrial fraction of human peripheral blood mononuclear
cells (hPBMCs), normal hepatocytes and human cell lines were prepared, and the CK activity was determined. (c) The immunocomplex proteins
of the anti-CKB or anti-ubiquitous mitochondrial CK (uMtCK) antibodies were analysed by CK activity assay. Specific CK activity was defined in
terms of units per cell (U/cell). The immunoprecipitated proteins were detected by immunoblotting analysis with an anti-CKB antibody and an
anti-Myc antibody (for ASB9) (lower panel).
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Page 16 of 22complex [23]. Here, we noticed that ASB9ΔSOCS is
naturally present in human cell lines. Interestingly,
ASB9ΔS O C Si sn o te x p r e s s e di nt h eP B M C sf r o m
diverse blood samples and normal hepatocytes (Figures
1 and 3). In the process of cell line establishment, chro-
mosomal rearrangements, insertions, and/or deletions
are commonly observed. Given the importance of the
SOCS box in ASB9, it is possible that induction of
ASB9ΔSOCS by genetic alterations may inhibit normal
function of ASB9 and have implications in the regula-
tion of target proteins and cell growth. Recently, ASB9
was isolated as a potential biomarker for breast cancer
[24]. It will be interesting to investigate whether the
reported increase of ASB9 expression is derived from
upregulation of ASB9ΔSOCS rather than ASB9 in breast
cancer cells.
On the basis of the proteomics approach, we con-
firmed that ASB9 interacts with CKs and ubiquitin
ligase complexes in the HEK293 cells that stably express
Myc-tagged ASB9 (Figures 4 and 5). The peptides iden-
tified from the ASB9 interacting proteins covered 27%
and 4% of the entire CKB and uMtCK proteins, respec-
tively (Figure 4 and Table 1). In this study, we identify
for the first time that uMtCK is a new target of ASB9,
in addition to CKB. Because the co-operative involve-
ment of cytosolic CKs and mitochondrial CKs is
required for a functional phosphocreatine circuit
[10-14], it is ideal that ASB9 recruits and regulates CKB
in cytosol and uMtCK in mitochondria. According to
the transfection and immunoprecipitation study, the
ANK repeat domains of ASB9 can associate with the
substrate binding site of uMtCK (Figures 7 and 8). This
result is in agreement with previous reports on the
binding properties of Asbs and CKs. Furthermore, the
expression of ASB9 induces the ubiquitination of
uMtCK and CKB in vivo and in vitro (Figures 9 and 10).
As a result, the protein levels of uMtCK and CKB were
clearly reduced after long-term culture for 10 passages
(Figure 11).
Given that ASB9 interacts with uMtCK, we reasoned
that the two proteins colocalise in the mitochondria.
ASB9 or ASB9ΔSOCS colocalised with endogenous
uMtCK in the mitochondria as expected (Figure 12).
Interestingly, the expression of ASB9 induced an abnor-
mal mitochondrial structure and loss of membrane
potential. Nowadays, the paradigm of the mitochondrial
function is changing: mitochondria are considered not
merely simple ATP-generating organelles but complex
integrators of cellular signalling pathways [29,30]. Stu-
dies that use fluorescence staining in live cells to investi-
gate the structure of mitochondria suggest that
mitochondria are highly dynamic [31]. Furthermore,
mitochondrial alterations appear to be a factor in cancer
[32,33]. Therefore, the abnormal structure of mitochon-
dria (Figure 12) and loss of ΔΨm( F i g u r e1 3 )m a yb e
direct evidence that ASB9 severely interrupts the normal
function of mitochondria. Previous studies by many
investigators have shown that MtCK proteins form an
active octameric complex with an internal channel that
stabilises the contact site between the outer membrane
and the inner membrane and that this behaviour may
be essential for the proper function [13,14]. Moreover,
under situations of a compromised cellular energy state,
such as ischaemia, oxidative stress, and calcium over-
load, MtCK seems to be a susceptible target for oxida-
tion; compensatory upregulation of MtCK gene
Figure 15 Effect of human ankyrin repeat and suppressor of cytokine signalling (SOCS) box protein 9 (ASB9) on cell growth. The cell
growth was measured during a 4-day culture of the human embryonic kidney 293 (HEK293) cells that stably express null, Myc-tagged ASB9, or
ASB9ΔSOCS. Cell growth was measured by means of a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (a) and a trypan
blue exclusion assay (b).
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Page 17 of 22expression has also been reported [18,19]. In addition,
the downregulation of uMtCK by small interfering RNA
(siRNA) in HaCaT and HeLaS3 cells reportedly affects
cell viability and mitochondrial morphology [34]. There-
f o r e ,t h et a r g e t i n go fA S B 9t ou M t C Ki sq u i t ep r o p e r
for efficient regulation of cell growth. The association
with ASB9 and degradation via ubiquitination may
reduce the level of monomeric uMtCK as well as active
oligomeric uMtCK and lead to an abnormal mitochon-
drial structure and function.
The expression of ASB9 was correlated with the
enzyme activity of the target substrates CKB and
uMtCK (Figure 14). Furthermore, the cellular CK activ-
ity of the total, cytosolic, and mitochondrial fractions
were all significantly reduced by ASB9 but not by
ASB9ΔSOCS. When we measured the activity of CKB
and uMtCK after immunoprecipitation with anti-CKB
or anti-uMtCK, the results clearly show that the activity
of CKB and uMtCK was abolished by ASB9 and
decreased by ASB9ΔSOCS. The association of ASB9Δ-
SOCS with uMtCK is likely to inhibit the enzymatic
activity even though uMtCK is not ubiquitinated and
degraded. The difference in the CK activity of cell
lysates and immunoprecipitates may be derived from
the residual adenylate kinase activity in the cell lysates.
Note also that the structure of the high-energy phos-
phate transfer system is reportedly rather complex
because adenylate kinase can compensate for the
decrease of CK activity when the action of CKs is
reduced [35]. The inhibition of CKB and uMtCK activity
by ASB9 is also linked to cell growth (Figure 15). How-
ever, as with the CK activity in cell lysates, ASB9ΔSOCS
did not show any significant inhibition of cell growth.
Therefore, the CK activity of cell lysates may represent
the real state of the compromised cells that use a cellu-
lar buffer system, possibly adenylate kinases, to control
the interruption by ASB9ΔSOCS.
Conclusions
Our results consistently show that ASB9 targets uMtCK
in addition to CKB for degradation, leading to negative
regulation of the creatine kinase system and cell growth.
Co-operative inhibition of CKB and uMtCK in cytosol
and mitochondria may be an efficacious strategy used
by ASB9 for the regulation of the cellular energy state.
ASB9ΔSOCS can associate with CKs but cannot recruit
the E3 ligase complex and ubiquitinate CKB and
uMtCK. Thus, ASB9ΔSOCS is likely to be a negative
regulator against the function of ASB9. Perhaps the reg-
ulation of ASB9 and ASB9ΔSOCS expression will be an
escaping strategy for cancer cells or established cell lines
from the suppressive function of ASB9. Because the
physiological meaning of ASB9ΔSOCS in human cell
lines and cancer may give insights into cancer biology,
further study on the function of ASB9ΔSOCS is
warranted.
Methods
Antibodies and plasmids
The anti-Myc and anti-ASB9 antibodies were purchased
from Cell Signaling Technology (Beverly, MA, USA) and
Abnova (Taipei City, Taiwan), respectively; and the anti-
CKB, anti-uMtCK, anti-elongin B, and anti-ubiquitin
antibodies were obtained from Santa Cruz (Santa Cruz,
CA, USA). The anti-HA and anti-Flag antibodies were
o b t a i n e df r o mS i g m aA l d r i c h( S tL o u i s ,M O ,U S A ) ,
while the anti-goat-Alexa fluor 488 and anti-mouse-
Alexa fluor 633 were obtained from Molecular Probes
(Eugene, OR, USA). The FLAG-tagged ubiquitin expres-
sion vector (pCS4-Flag-Ub) was described previously
[36]. The pDSRed2-Mito vector for the detection of
mitochondria was purchased from Clontech (Mountain
View, CA, USA).
Mice
Mice were maintained under specific-pathogen-free con-
ditions. Male BALB/c mice (4 weeks old) were pur-
chased from Central Lab. Animal Inc. (Seoul, Korea).
Our animal studies were approved by the Institutional
Animal Care and Use Committee of Hallym University
(Hallym 2008-12). The mice were killed and the perito-
neal cells, splenocytes and thymocytes were collected.
Total RNA isolation and reverse-transcription PCR analysis
Total RNAs were extracted with an RNeasy Mini Kit (Qia-
gen, Germantown, MD, USA), and the cDNA was gener-
ated as described previously [37]. The standard PCR
reaction was performed for 25 cycles with the following
primer sets: human b-actin, 5’-GGGTCAGAAG-
GATTCCTATG-3’ and 5’-CCTTAATGTCACGCAC-
GATTT-3’;C K B ,5 ’-ATCGACGACCACTTCCTCTT-3’
and 5’-ACCAGCTCCACCTCTGAGAA-3’;a n du M t C K ,
5’-AGCTTATTGATGACCACTTTCT-3’ and 5’-GACG-
CCGTTCACAATCAATC-3’. mouse glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), 5’-ATGGTGAA-
GGTCGGTGTGAACG-3’ and 5’-GTTGTCATGGAT-
GATCTTGGCC-3’;m A s b - 9 ,5 ’-TTCGGAGCAAACG-
CTCAAGCC-3’ and 5’-CTTCATTCTGCAAGAA-
GATCTGGAT-3’. To analyse the expression of 18 mem-
bers of the ASB family, we used the primers as described
in Table 2. For quantitative analysis of the tissue distribu-
tion of ASB9, we performed a real-time PCR by using the
cDNAs from several human tissues (Clontech) and by
using the CYBR Green Master Mix with 5’-AAAACC-
TAAGCCCTAATCTGTTGACA-3’ and 5’-AGGAC-
GAGTTTGGTTATCTTATGATG-3’ as primers. The
samples were run and analysed with the ABI 7000
machine (Applied Biosystems, Foster City, CA, USA).
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ASB9 and uMtCK
The ASB9 and ASB9ΔSOCS cDNAs were amplified
from HEK293 cells by RT-PCR using the following pri-
mer sets: ASB9 and ASB9ΔSOCS 5’ primer, 5’-CTCGA-
GATGGATGGCAAACAAGGGGG-3’;A S B 93 ’primer,
5’-GGTACCAGATGTAGGAGAAACTGTTTC-3’;a n d
ASB9ΔSOCS 3’ primer, 5’-TGGTACCGGCTTAGG-
TTTTGGCAAAG-3’. The nucleotide sequences of the
cDNAs were verified by DNA sequencing and a BLAST
search. The ASB9 ANK repeat deletion mutants were
generated by PCR using the following primers in
combination with ASB9 3’ primer: ASB9ΔANK1 5’-pri-
mer, 5’-CTCGAGATGGATCATGTTTCCCCACTCC-3’;
ASB9ΔANK1-2 5’-primer, 5’-CTCGAGATGGACTGG-
CACACTCCACTG-3’;A S B 9 ΔANK1-3 5’-primer, 5’-
CTCGAGATGCTGGCATCCCCCATCCAT-3’;a n d
ASB9ΔANK1-5 5’-primer 5’-CTCGAGATGCAG-
GATTCCCCACTTCATG-3’. The uMtCK cDNA from
HEK293 cells was amplified by RT-PCR with 5’-primer,
5’-GGATCCAAATGGCTGGTCCCTTCTC-3’ and 3’-
primer, 5’-AAGCTTTATAGGGAGGCTAGCTATCTA-
3’. To delete the BS of uMtCK (amino acids 135 to
145), we used the two primer sets: one for the partial
uMtCK sequence covering downstream of BS, 5’-
GGTACCGTGGTGGATGCACTGAGTG-3’ and uMtCK
3’ primer; and one for the partial uMtCK sequence
encoding upstream of BS, uMtCK 5’ primer and 5’-
TTGCTGACCTGTTTGACCCTGGTACC-3’.T h et w o
partial sequences were ligated by using the KpnIr e s t r i c -
tion enzyme site. The cDNA fragments were cloned into
the mammalian expression vectors pcDNA-3.1/Myc-His
(-)B (Invitrogen, Carlsbad, CA, USA) (ASB9, ASB9ΔSOCS
and ASB9ΔANK) and pcDNA-3.1/HA (uMtCK and
uMtCKΔBS).
Cell culture and construction of stable cell lines
Human keratinocyte (HaCaT) cells were kindly provided
by Professor N Fusenig (German Cancer Research Center,
Heidelberg, Germany). The human embryonic kidney cell
(HEK293), human B cell (RPMI 8226), human acute
monocytic leukaemia cell (THP-1), human myeloid cell
(KG-1), human hepatoma liver carcinoma cell (HepG-2)
and human hepatoma cell (Huh-7) lines were obtained
from the American Type Culture Collection (ATCC, Man-
assas, VA, USA). The human hepatocellular cell lines
(SNU-398, SNU-423, SNU-739 and SNU-761) were from
the Korean Cell Line Bank (Seoul, Korea). The HaCaT
and HEK293 cells were maintained in Dulbecco’s modified
Eagle medium (DMEM) with 10% fetal bovine serum
(FBS; Hyclone, Logan, UT, USA). The RPMI 8226, THP-1,
HepG-2, Huh-7, SNU-398, SNU-423, SNU-739 and SNU-
761 cells were maintained in an RPMI 1640 medium with
10% FBS, and the KG-1 cells were maintained in Iscove’s
modified Dulbecco’s media (IMDM) with 20% FBS. The
human normal hepatocyte cell (Promo Cell, Heidelberg,
Germany) was maintained as the vendor suggested with
Institutional Review Board approval. All cells were cul-
tured at 37°C in an atmosphere of 95% air and 5% CO2.
For the generation of ASB9 and ASB9ΔSOCS-expressing
stable cell lines, the HEK293 cells were transfected with
FuGENE 6 (Roche, Indianapolis, IN, USA) and the cells
were selected in 500 μg/ml G418 (Duchefa Biochemie,
Haarlem, The Netherlands) for 14 days. The expression of
Myc-tagged ASB9 and ASB9ΔSOCS was confirmed by
means of immunoblotting with the anti-Myc antibody.
Table 2 RT primer sequences for human ankyrin repeat
and suppressor of cytokine signalling (SOCS) box
proteins (ASBs)
Gene Direction Sequence Size (bp)
ASB1 Sense 5’-GTATGTGGCTGTGGTGAACG-3’ 359
Antisense 5’-AGCCCCTGTAGAATCCCTGT-3’
ASB2 Sense 5’-CCAAGAAGGGCAACTACAGG-3’ 382
Antisense 5’-GCGATATAGGCGTCGATGTT-3’
ASB3 Sense 5’-TTACTAACCGGGCCTGTGAC-3’ 395
Antisense 5’-AACCAGAAGATGTGGCAACC-3’
ASB4 Sense 5’-CTTGTGAAATGGCCAATGTG-3’ 392
Antisense 5’-TTCGGCTTTGTAGTCAAGCA-3’
ASB5 Sense 5’-ATGGCGTGACTCCGTTATTC-3’ 337
Antisense 5’-TCTGTGCTGGATTGTTGAGC-3’
ASB6 Sense 5’-ACCTGCATCATCTTCCTGCT-3’ 361
Antisense 5’-TCACCATGAGATCCAGGACA-3’
ASB7 Sense 5’-TGGAGTTCAAGGCTGAGGTT-3’ 316
Antisense 5’-GTGTTCGTGTCTGCTCCGTA-3’
ASB8 Sense 5’-ATGAGGCTTGTGTGGAGGTC-3’ 316
Antisense 5’-TCTGTTCCAAGTCCCCTGAC-3’
ASB9 Sense 5’-TGGCCCAGCTCTTCTTGGAG-3’ 115
Antisense 5’-AGGACGAGTTTGGTTATCTTATGATG-3’
ASB10 Sense 5’-GCTCCTGATTCCGTCTTTGA-3’ 395
Antisense 5’-ACTCTCGCTCCAAACCTGAG-3’
ASB11 Sense 5’-AAGACCTCCAAGGACGAAGC-3’ 152
Antisense 5’-CCAGCAATCTCCCTGAAATG-3’
ASB12 Sense 5’-ATGTTCTGGCCCCCTCTATT-3’ 326
Antisense 5’-GGACGACTAAACGGACCTGT-3’
ASB13 Sense 5’-CCGAATGTGTGAGGCTTCTT-3’ 375
Antisense 5’-CAGTGGCCTTCCTCAAGTTC-3’
ASB14 Sense 5’-CAAGCTGCTTCTGAGTGCTG-3’ 557
Antisense 5’-GAGAGATGTTGCAGCCATGA-3’
ASB15 Sense 5’-AATGCAATTCGGAAAAGTGG-3’ 363
Antisense 5’-AATGACACTGGGGAAACGAG-3’
ASB16 Sense 5’-AGACTGTGCTCGACACCTGA-3’ 117
Antisense 5’-CAGAGGTGCAAAGGAGTCGT-3’
ASB17 Sense 5’-GGGTTTTTGCCAGAAAAGGT-3’ 307
Antisense 5’-TCAGCCAATTCACGATCAAC-3’
ASB18 Sense 5’-GATGAGATGGAATGGCAGGT-3’ 312
Antisense 5’-GGGACAGATGCACAGGTCTT-3’
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The cells were lysed for 30 min at 4°C in an immuno-
precipitation (IP) buffer (10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), pH 7.4, 150 mM
NaCl, 5 mM ethylenediaminetetraacetic acid (EDTA),
complete protease inhibitor cocktail (Roche), 100 mM
NaF and 2 mM Na3VO4) supplemented with 1.0% nonyl
phenoxylpolyethoxylethanol (NP-40). Cell debris was
removed by centrifugation, and cell lysates were incu-
bated with the indicated antibodies for 2 h at 4°C. Pro-
tein A-Sepharose CL-4B (10% (v/v) slurry, Amersham
Pharmacia Biotech, Piscataway, NJ, USA) was added,
and the reaction mixtures were subjected to an addi-
tional 2 h of incubation at 4°C. The immunocomplexes
collected by centrifugation were washed twice with an
IP buffer that contained 0.1% NP-40.
Protein identification by mass spectrometry
Immunocomplexes were resolved by 15% SDS-PAGE
and stained with Coomassie brilliant blue G-250. For
identification of ASB9 and its binding proteins, the pro-
tein bands were digested in gel with trypsin and the
resulting peptides were then purified with a POROS R2
column (Applied Biosystems) to concentrate and desalt
the sample. The samples were analysed by electrospray
ionisation-time of flight mass spectrometry/mass spec-
trometry (ESI-TOF MS/MS) using a Micromass Q-TOF
MA equipped with a nanospray source (Waters, Milford,
M A ,U S A )i na nI n 2g e nf a c i l i t y( S e o u l ,R e p u b l i co f
Korea). The resulting amino acid sequences were further
analysed using the database managed by the National
Center for Biotechnology Information http://www.ncbi.
nlm.nih.gov.
Immunoblotting analysis
The immunocomplexes and cell lysates were resolved by
12.5% SDS-PAGE. The separated proteins were trans-
ferred to a nitrocellulose membrane (Bio-Rad, Hercules,
CA, USA), blocked in PBS containing 0.05% Tween-20
and 3% skim milk for 1 h, and incubated with the indi-
cated antibodies for 2 h at room temperature. Immunor-
eactive proteins were detected by means of a
horseradish peroxidase-conjugated secondary antibody
(Cell Signaling Technology) and an enhanced chemilu-
minescence reagent (Amersham Pharmacia Biotech).
In vitro ubiquitination assay
Immunocomplexes obtained by anti-CKB or anti-
uMtCK antibodies were mixed with 50 μl of a reaction
buffer containing 20 mM HEPES (pH 7.3), 10 mM
MgCl2, 2 mM ATP, 1 mM dithiothreitol, 5 μg/ml Ub,
50 μM Ub-activating enzyme (E1), and 1 μM ubiquitin-
conjugating enzyme (E2-UbcH5a) (Boston Biochem,
Cambridge, MA, USA) and incubated for 1.5 h at 37°C.
Polyubiquitination was identified by SDS-PAGE and
immunoblotting analysis with the anti-ubiquitin
antibody.
Immunofluorescence staining and confocal microscopy
The cells were cultured on glass coverslips in 12-well
plates for 24 h and transfected with a pDSRed2-Mito
vector (Clontech) for the detection of mitochondria.
After 24 h, cells were fixed with 4% paraformaldehyde,
permeabilised with 0.1% Triton X-100, incubated with
antibodies against Myc epitope (for ASB9) and uMtCK,
and then incubated with Alexa fluor 633 conjugated
goat anti-mouse IgG and Alexa fluor 488 conjugated
donkey anti-goat IgG (Molecular Probes). Nuclei were
stained with Hoechst no. 33258. The mounted samples
were scanned with an LSM 510 microscope (Carl Zeiss,
Jena, Germany). For three-dimensional analysis of mito-
chondrial structure in control cells and ASB9 overex-
pressing cells, we acquired Z-scan images with a Z-slice
interval 0.34 μM. A three-dimensional animation file
was converted with angle degree 6° using LSM510
META software (Carl Zeiss) for three-dimensional
reconstruction (see Additional files 1 and 2).
Analysis of mitochondrial membrane potential
To measure the ΔΨm, we incubated the cells with 50
nM TMRE (Sigma Aldrich) for 30 min at 37°C. FCCP
(Molecular Probes) was treated for 30 min at 37°C as an
uncoupler. The cells were analysed with a FACScan
flow cytometer (BD Biosciences, San Jose, CA, USA) to
monitor the TMRE fluorescence (582 nm, FL-2
channel).
Mitochondrial fractionation
The mitochondrial fractions were isolated using a mito-
chondrial fractionation kit (Active Motif, Carlsbad, CA,
USA) in accordance with the manufacturer’s specifica-
tions. After the cells were washed and homogenised, the
cell debris was removed by centrifugation at 800 g for
20 min at 4°C; the supernatants were then centrifuged
at 10,000 g for 20 min at 4°C to separate the mitochon-
drial (pellets) and the cytosolic fraction (supernatants).
CK activity assay
The CK activity was determined with the EnzyChrom
Creatine Kinase Assay Kit (BioAssay Systems, Hayward,
CA, USA) in accordance with the manufacturer’s specifi-
cations. The colour development was measured at
340 nm. The specific CK activity was defined in terms
of units per cell (U/cell).
Cell viability assay
The cell growth of the HEK293 cells was determined
by an MTT assay with a MTT solution (Sigma
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assay, the cells were seeded in 48-well plates. After the
indicated culture periods, the MTT solution was added
to each well and the plates were incubated for an addi-
tional 4 h at 37°C. After removal of the medium, the
formazan crystals were solubilised in dumethylsuflox-
ide (DMSO). The colour development was monitored
by a spectrophotometer at 595 nm with a reference
wavelength of 650 nm. The number of viable cells was
counted by means of the trypan blue dye exclusion
method.
Additional file 1: Movie 1. For three-dimensional analysis of
mitochondrial structure in control cells, we acquired Z-scan image with
Z-slice interval 0.34 μM. The three-dimensional animation file was
converted with angle degree 6° using LSM510 META software for three-
dimensional reconstruction.
Additional file 2: Movie 2. For three-dimensional analysis of the
mitochondrial structure of human ankyrin repeat and suppressor of
cytokine signalling (SOCS) box protein 9 (ASB9) (movie 2) overexpressing
cells (see Figure 12b), we acquired Z-scan image with Z-slice interval 0.34
μM. The three-dimensional animation file was converted with angle
degree 6° using LSM510 META software for three-dimensional
reconstruction.
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